Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma

M. Cavo, L. Pantani, A. Pezzi, M. T. Petrucci, F. Patriarca, F. Di Raimondo, G. Marzocchi, M. Galli, V. Montefusco, E. Zamagni, B. Gamberi, P. Tacchetti, A. Brioli, A. Palumbo, P. Sonneveld

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)2429-2431
Number of pages3
JournalLeukemia
Volume29
Issue number12
DOIs
Publication statusPublished - Dec 1 2015

ASJC Scopus subject areas

  • Hematology
  • Cancer Research
  • Anesthesiology and Pain Medicine

Cite this

Cavo, M., Pantani, L., Pezzi, A., Petrucci, M. T., Patriarca, F., Di Raimondo, F., Marzocchi, G., Galli, M., Montefusco, V., Zamagni, E., Gamberi, B., Tacchetti, P., Brioli, A., Palumbo, A., & Sonneveld, P. (2015). Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma. Leukemia, 29(12), 2429-2431. https://doi.org/10.1038/leu.2015.274